3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
4
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
45
Sarcoma
33
Lymphoma, Large B-Cell, Diffuse
32
Neoplasms
25
Lymphoma
20
Lymphoma, Non-Hodgkin
19
Ovarian Neoplasms
17
Lymphoma, Follicular
16
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Lymphoma, B-Cell
11
Endometrial Neoplasms
11
Recurrence
10
Carcinoma, Hepatocellular
8
Hodgkin Disease
7
Lymphoma, T-Cell, Peripheral
6
Hematologic Diseases
6
Sarcoma, Kaposi
5
Lymphoma, Mantle-Cell
5
Leiomyosarcoma
5
HIV Infections
5
Acquired Immunodeficiency Syndrome
5
Multiple Myeloma
4
Liposarcoma
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lymphoma, B-Cell, Marginal Zone
3
Liver Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Fallopian Tube Neoplasms
3
Interventions
Bevacizumab
27
Leucovorin
23
Fluorouracil
22
Oxaliplatin
17
Irinotecan
15
Cetuximab
14
pembrolizumab
11
IFL protocol
11
Panitumumab
10
Folfox protocol
10
Capecitabine
10
Gemcitabine
7
adagrasib
5
Cisplatin
5
Carboplatin
5
Ramucirumab
4
Colonoscopy
4
veliparib
3
spartalizumab
3
selpercatinib
3
regorafenib
3
labetuzumab
3
durvalumab
3
conatumumab
3
cemiplimab
3
Pemetrexed
3
Paclitaxel
3
HMPL-013
3
Drug Therapy
3
5,11-methenyltetrahydrohomofolate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colonic Neoplasms
×
Doxorubicin
×
Clear all
NCT01464593
2022-10-13
ABLATE
Imunon
Phase 2
Terminated
2 enrolled
5 charts